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Conclusion: PTV-FDG typically covers PTV-FMISO only partially and is on average two times larger. Therefore, a dose escalation in the metabolically active sub-volume partially misses the hypoxic sub-volume. The large volume difference suggests that a substantially higher dose escalation is feasible in PTV-FMISO than in PTV-FDG. Clinical trials are required to compare the efficacy of both methods. Purpose or Objective: Patients with locally advanced rectal cancer (LARC) are commonly treated with neoadjuvant chemoradiotherapy (CRT) followed by radical surgery. However, tumor responses vary considerably and about one third of the patients experience poor disease outcome due to metastatic progression. We aimed to investigate if apparent diffusion coefficients (ADCs) quantified from diffusionweighted MRI (DWMRI) predicted histologic tumor response to the neoadjuvant treatment and long-term survival.
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Recognizing the tumor heterogeneity we specifically aimed to explore if histogram analysis of tumor ADC may reveal more useful information than the commonly used mean ADC measure.
Material and Methods: Data from 23 prospectively enrolled patients receiving induction neoadjuvant chemotherapy (NACT) followed by CRT and radical surgery was analyzed. DWMRI was acquired at baseline and after NACT. Tumor volumes contoured in T2-weighted MR images were transferred to tumor ADC maps calculated with b-values 300 and 900 s/mm2, before ADCs were extracted from all tumor voxels and presented as histograms. The predictive information contained in the histograms was evaluated using receiver operating characteristic (ROC) curve analysis of each percentile from 1-100. Study endpoints were histologic tumor regression grade (TRG) and 5-year progression-free survival (PFS).
Results:
Using the change in tumor ADC from baseline to NACT completion, we identified a histogram area below median (20th-40th percentiles) to be associated with both TRG and PFS. By using the 20th percentile, an increase in S448 ESTRO 35 2016 ______________________________________________________________________________________________________ ADC predicted poor histologic tumor response (TRG3-5 versus TRG1-2) with 91% sensitivity and 83% specificity (area under curve (AUC)= 0.89, 95% confidence interval (CI)= 0.74-1.0, p= 0.001). Using the 30th percentile, an increase in ADC predicted poor PFS with 89% sensitivity and 71% specificity (AUC=0.75, 95% CI=0.54-0.95, p=0.051). Univariate regression analysis also revealed that the ADC increase was significantly associated to poor PFS (hazard ratio=9.7, 95% CI=1.21-78.30, p=0.033).
Conclusion:
By ADC histogram analysis of DWMRI acquired during NACT of LARC we identified low histogram percentiles as predictive of histologic tumor response in particular, but also long-term survival. The results require validation in larger, independent cohorts, but are promising for identification of patients that may benefit from individualized treatment approaches for improved disease outcome. Purpose or Objective: Tumor hypoxia is prognostic for poor outcome after radiotherapy (RT). A method for non-invasive assessment of hypoxia is PET using hypoxia radiotracers such as FMISO. The goal of this study was to develop and evaluate a tool to simulate 3D oxygen distribution and the resulting FMISO accumulation on realistic vessel architectures, which can be compared to measured PET activities in small animal experiments.
PO-0925 Simulation of FMISO diffusion-retention in a three

Material and Methods: Two FaDu tumors (human HNSCC)
were grown on the right hind leg of nude mice. Imaging was performed after a growth phase of about 5 weeks. FMISO was injected into the tail vein of the anesthetized mice with an activity of ~12MBq for dynamic PET/MRI. ROIs inside the left ventricle and in the tumor were chosen to determine blood and tumor time activity curves (TACs). After image acquisition tumors were excised, snap frozen and cut into consecutive sections (20µm). Sections were stained with immunoflourescence-labeled antibodies for endothelial marker CD31 and scanned with a Zeiss Axioplan 2 fluorescence microscope. Obtained immunofluorescence images were rigidly registered, manually adjusted and thresholded to create a binary 3D vessel map. These maps were used to simulate 3D oxygen distributions based on a Michaelis-Menten relation. Using the oxygen distribution and the dynamic activity in the left ventricle as input, FMISO retention was simulated on the same vessel maps. A tumor ROI was selected and its average activity at different time points post-injection (p.i.) compared against the measured activity in the same region on the PET scan (tumor TAC). To compare 3D and 2D simulations, the simulation were repeated in 2D on the individual sections, and 2D-based oxygen histograms and TACs were determined.
Results: O2 histograms showed a large difference between 2D and 3D simulations, with much lower values for 2D simulations than for 3D (5.94 mmHg vs 26.57 mmHg). Mean values were closer together (8.9 mmHg vs 13.2 mmHg). This is due to the large amount of anoxic voxels (pO2 < 1 mmHg) in the 2D simulation, which made up 17.5% of all simulated voxels in 2d, but less than 1% in the 3D simulations (see Table  1 ). Visually, the 3D simulations result in a TAC with a similar overall shape compared to the TAC measured with small animal PET, but with a 20.7% overestimation of activity. However, the 2D simulations severely overestimated the total activity by 99.2% (2D) when compared against measured activity in the tumor after 90min as determined by PET.
Conclusion: 3D simulations based on real 3D vessel architecture is feasible. Our FMISO simulations showed large discrepancies between 2D and 3D simulation approaches, with the 3D values being closer to the PET measurements. Verification of 3D tracer accumulation patterns in additional tumors against pimonidazole stainings is still necessary to validate and calibrate the method, with PET scans in the same test subject to confirm observed activity.
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Voxel-based PSMA-PET/histopathology analysis in patients with primary prostate cancer C. Zamboglou
